Abstract:Components of the cell cycle machinery are frequently altered in cancer. Many of these alterations affect the cyclin-dependent kinases (CDKs) and their regulation. Staurosporine and 7-hydroxystaurosporine (UCN-01) are two natural product kinase inhibitors originally identified as potent protein kinase C inhibitors. Staurosporine is non-selective and too toxic for use in therapy, but UCN-01 shows greater selectivity, and is in clinical trials. We have determined the crystal structures of staurosporine bound to monomeric CDK2 and UCN-01 bound to active phospho-CDK2/cyclin A. Both compounds mimic the hydrogen bonds made by the adenine moiety of ATP, and both exploit the non-polar nature of the adenine-binding site. In the complex with UCN-01, a hydrogen-bonded water molecule is incorporated into the non-polar cavity, which provides a partial polar character in the environment of the 7-hydroxyl group. Comparison of the ATP-binding site of CDK2 with that of other kinases reveals that in Chk1 kinase, a major target for UCN-01 in the cell, one of the surrounding residues, Ala144 in CDK2, is a serine in Chk1, thus providing a possible explanation for the effectiveness of UCN-01 against this kinase. For cells to exit mitosis, the CDKs must be completely inactivated, firstly by the ubiquintin-mediated destruction of the cyclins, followed by dephosphorylation of phospho-Thr160 (in CDK2) catalysed by the kinase-associated phosphatase and protein phosphatase 2C. We describe the structure of phospho-CDK2 in complex with kinase-associated phosphatase, and discuss the substrate recognition promoted by interactions that are remote from the catalytic site.

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Small Molecule Modulators Targeting Protein Kinase CK1 and CK2

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.

Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification.

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Recent Advances in the Discovery of CK2 Inhibitors

Achieving Effective and Selective CK1 Inhibitors Through Structure Modification.

Newly Developed CK1-Specific Inhibitors Show Specifically Stronger Effects on CK1 Mutants and Colon Cancer Cell Lines

A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies

Exploring The Pivotal Role Of The Ck2 Hinge Region Sub-Pocket In Binding With Tricyclic Quinolone Analogues By Computational Analysis

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening.

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Regulation of cancer progression by CK2: an emerging therapeutic target

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity

Inhibitors and PROTACs of CDK2: challenges and opportunities